目的 探討豨薟通栓膠囊聯(lián)合丁苯酞軟膠囊治療急性腦梗死的臨床療效。方法 選取2019年2月-2020年2月南開大學(xué)附屬醫(yī)院收治的92例急性腦梗死患者作為研究對象，按照隨機數(shù)字表法將全部患者分為對照組和治療組，每組各46例。對照組口服丁苯酞軟膠囊，2粒/次，3次/d。治療組在對照組治療的基礎(chǔ)上口服豨薟通栓膠囊，3粒/次，3次/d。兩組患者連續(xù)治療4周。觀察兩組的臨床療效，比較兩組的NIHSS評分、白細胞介素-6（IL-6）、同型半胱氨酸（Hcy）、腦源性神經(jīng)營養(yǎng)因子（BDNF）、中樞神經(jīng)特異蛋白（S100β）、血漿比黏度、纖維蛋白原、D-二聚體。結(jié)果 治療后，治療組的總有效率（93.48%）明顯比對照組（78.26%）高，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的血漿比黏度、纖維蛋白原、D-二聚體顯著降低（P<0.05）；治療后，治療組的血漿比黏度、纖維蛋白原、D-二聚體均低于對照組，差異具有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組的IL-6、Hcy、BDNF、S100β蛋白顯著降低（P<0.05）；治療后，治療組的IL-6、Hcy、BDNF、S100β蛋白低于對照組，差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組患者的NIHSS評分均顯著降低（P<0.05），以治療組NIHSS評分降低的更明顯（P<0.05）。結(jié)論 豨薟通栓膠囊聯(lián)合丁苯酞軟膠囊治療急性腦梗死具有較好的療效，能減輕神經(jīng)組織的炎性損傷，改善血液流變學(xué)水平，減輕神經(jīng)功能缺損程度。

Objective To investigate the clinical effect of Xixian Tongshuan Capsules combined with Butylphthalide Soft Capsules in treatment of acute cerebral infarction. Methods Patients (92 cases) with acute cerebral infarction in the Affiliated Hospital of Nankai University from February 2019 to February 2020 were randomly divided into control and treatment groups, and each group had 46 cases. Patients in the control group were po administered with Butylphthalide Soft Capsules, 2 grains/time, three times daily. Patients in the treatment group were po administered with Xixian Tongshuan Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and NIHSS scores, IL-6, Hcy, BDNF, S100β protein, plasma specific viscosity, fibrinogen, and D-dimer in two groups were compared. Results After treatment, the total effective rate of the treatment group (93.48%) was significantly higher than that of the control group (78.26%), and the difference was statistically significant (P<0.05). After treatment, the plasma specific viscosity, fibrinogen, and D-dimer in two groups were significantly decreased (P<0.05). After treatment, the plasma specific viscosity, fibrinogen, and D-dimer in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the levels of IL-6, Hcy, BDNF, and S100β protein in two groups were significantly decreased (P<0.05). After treatment, the levels of IL-6, Hcy, BDNF, and S100β protein in the treatment group were lower than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the NIHSS scores of two groups were significantly decreased (P<0.05), and the NIHSS score of the treatment group was significantly lower than that of the control group (P<0.05). Conclusion Xixian Tongshuan Capsules combined with Butylphthalide Soft Capsules has clinical curative effect in treatment of acute cerebral infarction, can reduce the inflammatory injury of nerve tissue, improve the level of hemorheology, and reduce the degree of nerve function defect.

R971

天津市濱海新區(qū)衛(wèi)生局科技項目（2014BWKY013）